Page last updated: 2024-08-21

alpha-aminopyridine and Schizophrenia

alpha-aminopyridine has been researched along with Schizophrenia in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's1 (14.29)29.6817
2010's2 (28.57)24.3611
2020's3 (42.86)2.80

Authors

AuthorsStudies
Ffytche, D; Gilleen, J; Kerins, S; Lahu, G; Mehta, MA; Nottage, J; Ogrinc, F; Shergill, SS; Tsai, M; Uz, T; Valdearenas, L; Williams, SC; Yakub, F1
Gilleen, J; Hawkins, PC; Livingston, NR; Mehta, MA; Shergill, SS; Valdearenas, L; Ye, R1
Davison, C; Farah, Y; Gilleen, J; Kerins, S; Lahu, G; Mehta, MA; Ogrinc, F; Reichenberg, A; Shergill, SS; Tsai, M; Uz, T; Valdearenas, L; Williams, SC1
Ballard, TM; Hernandez, MC; Hoffmann, T; Knoflach, F; Malherbe, P; Porter, RH; Schnider, P; Spooren, W; Steward, L; Wettstein, JG1
Balsam, PD; Fairhurst, S; Kandel, ER; Kellendonk, C; Lipatova, O; Richards, V; Simpson, EH; Ward, RD1
Cosi, C; Newman-Tancredi, A; Rollet, K; Tesori, V; Waget, A1
Chari, S; Deth, RC; DuRand, CJ; Kotb, M; Kramer, ML; Liu, D; Nagata, M; Ouellette, D; Sharma, A; Shim, S; Tan, W; Wick, PF1

Trials

3 trial(s) available for alpha-aminopyridine and Schizophrenia

ArticleYear
The effects of roflumilast, a phosphodiesterase type-4 inhibitor, on EEG biomarkers in schizophrenia: A randomised controlled trial.
    Journal of psychopharmacology (Oxford, England), 2021, Volume: 35, Issue:1

    Topics: Adult; Aminopyridines; Benzamides; Cognition; Cognitive Dysfunction; Cross-Over Studies; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Double-Blind Method; Drug Monitoring; Electroencephalography; Evoked Potentials; Female; Humans; Male; Mental Processes; Phosphodiesterase 4 Inhibitors; Psychiatric Status Rating Scales; Schizophrenia; Treatment Outcome

2021
Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia.
    Journal of psychopharmacology (Oxford, England), 2021, Volume: 35, Issue:9

    Topics: Adult; Aged; Aminopyridines; Benzamides; Cognitive Dysfunction; Cross-Over Studies; Cyclopropanes; Dorsolateral Prefrontal Cortex; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Phosphodiesterase 4 Inhibitors; Prefrontal Cortex; Schizophrenia

2021
An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients.
    Psychopharmacology, 2021, Volume: 238, Issue:5

    Topics: Adult; Aminopyridines; Animals; Benzamides; Brain; Cognition; Cognition Disorders; Cross-Over Studies; Cyclopropanes; Double-Blind Method; Female; Humans; Male; Memory, Episodic; Memory, Short-Term; Middle Aged; Phosphodiesterase 4 Inhibitors; Prefrontal Cortex; Schizophrenia

2021

Other Studies

4 other study(ies) available for alpha-aminopyridine and Schizophrenia

ArticleYear
Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors.
    British journal of pharmacology, 2011, Volume: 162, Issue:4

    Topics: Action Potentials; Amides; Aminopyridines; Animals; Antipsychotic Agents; Benzeneacetamides; Dose-Response Relationship, Drug; Female; Gerbillinae; Guinea Pigs; HEK293 Cells; Humans; In Vitro Techniques; Inositol; Ligands; Macaca fascicularis; Male; Mesencephalon; Mice; Neurokinin-1 Receptor Antagonists; Neurons; Phosphorylation; Pyridines; Rats; Receptors, Neurokinin-1; Receptors, Neurokinin-3; Schizophrenia; Substance P; Substantia Nigra

2011
Pharmacologic rescue of motivational deficit in an animal model of the negative symptoms of schizophrenia.
    Biological psychiatry, 2011, May-15, Volume: 69, Issue:10

    Topics: Affective Symptoms; Aminopyridines; Analysis of Variance; Animals; Conditioning, Operant; Corpus Striatum; Disease Models, Animal; Gene Expression; Indoles; Mice; Mice, Transgenic; Motivation; Receptor, Serotonin, 5-HT2C; Receptors, Dopamine D2; Reward; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; Up-Regulation

2011
Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation.
    Brain research, 2005, May-10, Volume: 1043, Issue:1-2

    Topics: Aminopyridines; Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Corpus Striatum; Disease Models, Animal; Excitatory Amino Acid Agonists; Haloperidol; Kainic Acid; Male; Mice; Mice, Inbred C57BL; Piperazines; Piperidines; Pyridines; Quinolones; Receptor, Serotonin, 5-HT1A; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Thiazoles

2005
D4 dopamine receptor-mediated phospholipid methylation and its implications for mental illnesses such as schizophrenia.
    Molecular psychiatry, 1999, Volume: 4, Issue:3

    Topics: Amino Acid Sequence; Aminopyridines; Animals; Benzazepines; Binding Sites; Carbon Radioisotopes; CHO Cells; Clozapine; Cricetinae; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Formates; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Methionine; Mutagenesis, Site-Directed; Neuroblastoma; Phospholipids; Phosphorylation; Piperidines; Psychotic Disorders; Pyridines; Pyrroles; Raclopride; Receptors, Dopamine D2; Receptors, Dopamine D4; Recombinant Proteins; S-Adenosylmethionine; Salicylamides; Schizophrenia; Transfection; Tumor Cells, Cultured

1999